View all newsletters
Receive our newsletter - data, insights and analysis delivered to you

Mallinckrodt to fund nitric oxide therapy trial in Covid-19 patients

Mallinckrodt has agreed to fund a clinical trial conducted by US researchers to assess the use of its inhaled nitric oxide therapy, INOmax, to treat lung complications in Covid-19 patients.

The company would offer funding support, as well as INOmax, for the investigator-initiated trial at Massachusetts General Hospital.

The primary objective of the study is the potential efficacy of inhaled nitric oxide in reversing abnormally low oxygen levels in the blood of Covid-19 patients with severe lung complications.

Read the full article here

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena